Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7881-7890 Newer>

Pharmaceutical Executive September 1, 2011	Build It and They Will Come Orlando's new Burnham Research Institute bolsters the region's hold on medical meetings.
Pharmaceutical Executive September 1, 2011	(Some) Booths Beckon What some pharma companies are doing about the increasing restrictions of face-to-face interaction between industry and prescribing physicians.
Pharmaceutical Executive September 1, 2011 William Looney	Get Back in the Box! Despite the gloom, most forecasts show the US will stay atop the industry in profits for at least the next generation of products.
Pharmaceutical Executive September 1, 2011 Richard Gliklich	The Power of Observation Observational studies present a compelling real-world corollary to the classic randomized clinical trial.
Pharmaceutical Executive September 1, 2011 Richard Barker	Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Pharmaceutical Executive September 1, 2011 Al Topin	A Long, Slow Walk Toward the Altar Agency/client relationships still take time to build into successful marriages in this age of digital connections and me-first attitudes.
Pharmaceutical Executive September 1, 2011 Don Creighton	Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement.
Pharmaceutical Executive September 1, 2011 Jill B. Conner	Complex Biologics: The View from Teva Industry and regulators alike must grapple with the sensitivities associated with developing bio-similar drugs.
Pharmaceutical Executive September 1, 2011 Jill Wechsler	Rebates and Reform User-fee renewal legislation sets the stage for new policies affecting reimbursement, research, and regulatory oversight.
The Motley Fool September 14, 2011 Brian Orelli	How to Muck Up a Turnaround in 12 and a Half Months Boston Scientific's choice for a new CEO has the potential to really muck up its recovery even further -- if that's even possible.
<Older 7881-7890 Newer> Return to current articles.